Skip to main content
Erschienen in: Archives of Osteoporosis 1/2023

01.12.2023 | Original Article

Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males

verfasst von: Zaizhu Zhang, Qiang Lin, Ying Xu, Wenmin Guan, Xiaojing Song, Yanling Li, Yi Zhang, Taisheng Li, Wei Yu

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Summary

This is the first study to report both greater BMD loss and muscle loss in Chinese HIV-infected males with lamivudine (3TC)-tenofovir disoproxil fumarate (TDF)-efavirenz (EFV) regimen, which highlights the importance of closely monitoring muscle mass and bone mineral density in patients treated with 3TC-TDF-EFV regimen and provides a foundation for the clinical intervention of sarcopenia and osteoporosis.

Purpose

To compare the effect initiating different antiretroviral therapy (ART) regimens have on muscle mass, bone mineral density (BMD), and trabecular bone score (TBS).

Methods

We designed a retrospective study of ART-naive Chinese males with HIV (MWH) undergoing two different regimens at 1-year follow-up. All subjects underwent dual-energy absorptiometry (DXA) for BMD and muscle mass prior to ART initiation, and again 1 year later. TBS iNsight software was used for TBS. We analyzed differences in muscle mass, BMD, and TBS after different treatment arms and associations between ART regimens and changes in them.

Results

A total of 76 men were included (mean age 31.83 ± 8.75 years). Mean absolute muscle mass decreased significantly from baseline to follow-up after initiation of lamivudine (3TC)-tenofovir disoproxil fumarate (TDF)-efavirenz (EFV), whereas increased significantly after initiation of 3TC-zidovudine(AZT)/Stavudine(d4T)-Nevirapine(NVP). Assignment to 3TC-TDF-EFV resulted in greater percentage loss in BMD at lumbar spine (LS) and total hip (TH) compared to 3TC-AZT/d4T-NVP, but this difference was not statistically significant at the femoral neck BMD and TBS. In the multivariable logistic regression model adjusted for covariates, the 3TC-TDF-EFV regimen was associated with higher odds of decreased appendicular and total muscle mass, LS and TH BMD.

Conclusions

This is the first study to report not only greater BMD loss but also muscle loss in Chinese MWH with 3TC-TDF-EFV regimen. Our work highlights the importance of closely monitoring muscle mass and BMD in patients treated with 3TC-TDF-EFV regimen and provides a foundation for the clinical intervention of sarcopenia and osteoporosis in them.
Literatur
1.
Zurück zum Zitat Palella FJ Jr, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators. New England J Med 338(13):853–860CrossRef Palella FJ Jr, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators. New England J Med 338(13):853–860CrossRef
2.
Zurück zum Zitat Goh SSL, Lai PSM, Tan ATB et al (2018) Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporosis Int Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 29(3):595–613CrossRef Goh SSL, Lai PSM, Tan ATB et al (2018) Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporosis Int Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 29(3):595–613CrossRef
3.
Zurück zum Zitat Sax PE, Wohl D, Yin MT et al (2015) Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England) 385(9987):2606–2615CrossRefPubMed Sax PE, Wohl D, Yin MT et al (2015) Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England) 385(9987):2606–2615CrossRefPubMed
4.
Zurück zum Zitat Oliveira VHF, Borsari AL, Webel AR et al (2020) Sarcopenia in people living with the human immunodeficiency virus: a systematic review and meta-analysis. Eur J Clin Nutr 74(7):1009–1021CrossRefPubMed Oliveira VHF, Borsari AL, Webel AR et al (2020) Sarcopenia in people living with the human immunodeficiency virus: a systematic review and meta-analysis. Eur J Clin Nutr 74(7):1009–1021CrossRefPubMed
5.
Zurück zum Zitat Konishi K, Nakagawa H, Asaoka T et al (2022) Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition. Medicine 101(42):e31349CrossRefPubMedPubMedCentral Konishi K, Nakagawa H, Asaoka T et al (2022) Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition. Medicine 101(42):e31349CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Guimarães NS, Raposo MA, Greco D et al (2022) People Living With HIV, Lean mass, and sarcopenia: a systematic review and meta-analysis. J Clin Densitometry Official J Int Soc Clin Densitometry 25(1):113–123CrossRef Guimarães NS, Raposo MA, Greco D et al (2022) People Living With HIV, Lean mass, and sarcopenia: a systematic review and meta-analysis. J Clin Densitometry Official J Int Soc Clin Densitometry 25(1):113–123CrossRef
8.
Zurück zum Zitat Hawkins KL, Brown TT, Margolick JB, et al. Geriatric syndromes: new frontiers in HIV and sarcopenia. AIDS (London, England). 2017;31 Suppl 2(Suppl 2):S137-s146. Hawkins KL, Brown TT, Margolick JB, et al. Geriatric syndromes: new frontiers in HIV and sarcopenia. AIDS (London, England). 2017;31 Suppl 2(Suppl 2):S137-s146.
9.
Zurück zum Zitat Abdul Aziz SA, McStea M, Ahmad Bashah NS et al (2018) Assessment of sarcopenia in virally suppressed HIV-infected Asians receiving treatment. AIDS (London, England) 32(8):1025–1034CrossRefPubMed Abdul Aziz SA, McStea M, Ahmad Bashah NS et al (2018) Assessment of sarcopenia in virally suppressed HIV-infected Asians receiving treatment. AIDS (London, England) 32(8):1025–1034CrossRefPubMed
10.
Zurück zum Zitat Guo F, Song X, Li Y et al (2021) Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy. Osteoporosis Int J established as result of cooperation between the Euro Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 32(2):321–332CrossRef Guo F, Song X, Li Y et al (2021) Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy. Osteoporosis Int J established as result of cooperation between the Euro Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 32(2):321–332CrossRef
11.
Zurück zum Zitat Tao X, Lu Y, Zhou Y et al (2020) Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J infectious diseases: IJID: official publication Int Soc Infectious Dis 93:108–117 Tao X, Lu Y, Zhou Y et al (2020) Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J infectious diseases: IJID: official publication Int Soc Infectious Dis 93:108–117
12.
Zurück zum Zitat Stellbrink HJ, Orkin C, Arribas JR et al (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin infectious dis official publication of the Infectious Dis Soc Am 51(8):963–972CrossRef Stellbrink HJ, Orkin C, Arribas JR et al (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin infectious dis official publication of the Infectious Dis Soc Am 51(8):963–972CrossRef
13.
Zurück zum Zitat Guan WM, Pan W, Yu W et al (2021) Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy. J Orthopaedic Trans 29:72–77CrossRef Guan WM, Pan W, Yu W et al (2021) Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy. J Orthopaedic Trans 29:72–77CrossRef
14.
Zurück zum Zitat McComsey GA, Kitch D, Daar ES et al (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203(12):1791–1801CrossRefPubMedPubMedCentral McComsey GA, Kitch D, Daar ES et al (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203(12):1791–1801CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat McDermott AY, Shevitz A, Knox T et al (2001) Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 74(5):679–686CrossRefPubMed McDermott AY, Shevitz A, Knox T et al (2001) Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 74(5):679–686CrossRefPubMed
16.
Zurück zum Zitat Thompson V, Medard B, Taseera K et al (2011) Regional anthropometry changes in antiretroviral-naïve persons initiating a Zidovudine-containing regimen in Mbarara. Uganda AIDS Res Human Retroviruses 27(7):785–791CrossRef Thompson V, Medard B, Taseera K et al (2011) Regional anthropometry changes in antiretroviral-naïve persons initiating a Zidovudine-containing regimen in Mbarara. Uganda AIDS Res Human Retroviruses 27(7):785–791CrossRef
17.
Zurück zum Zitat Dubé MP, Qian D, Edmondson-Melançon H et al (2002) Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin infectious Dis official publication of the Infectious Dis Soc Am 35(4):475–481CrossRef Dubé MP, Qian D, Edmondson-Melançon H et al (2002) Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin infectious Dis official publication of the Infectious Dis Soc Am 35(4):475–481CrossRef
18.
Zurück zum Zitat Mallon PW, Miller J, Cooper DA et al (2003) Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (London, England) 17(7):971–979CrossRefPubMed Mallon PW, Miller J, Cooper DA et al (2003) Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (London, England) 17(7):971–979CrossRefPubMed
19.
Zurück zum Zitat Shikuma CM, Zackin R, Sattler F et al (2004) Changes in weight and lean body mass during highly active antiretroviral therapy. Clin infectious Dis official publication of the Infectious Dis Soc Am 39(8):1223–1230CrossRef Shikuma CM, Zackin R, Sattler F et al (2004) Changes in weight and lean body mass during highly active antiretroviral therapy. Clin infectious Dis official publication of the Infectious Dis Soc Am 39(8):1223–1230CrossRef
20.
Zurück zum Zitat Erlandson KM, Jiang Y, Debanne SM et al (2016) Effects of 96 weeks of rosuvastatin on bone, muscle, and fat in HIV-infected adults on effective antiretroviral therapy. AIDS Res Hum Retroviruses 32(4):311–316CrossRefPubMedPubMedCentral Erlandson KM, Jiang Y, Debanne SM et al (2016) Effects of 96 weeks of rosuvastatin on bone, muscle, and fat in HIV-infected adults on effective antiretroviral therapy. AIDS Res Hum Retroviruses 32(4):311–316CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Zhao DC, Wen Y, Ma Y et al (2012) Expansion of Chinaʼs free antiretroviral treatment program. Chin Med J 125(19):3514–3521PubMed Zhao DC, Wen Y, Ma Y et al (2012) Expansion of Chinaʼs free antiretroviral treatment program. Chin Med J 125(19):3514–3521PubMed
22.
Zurück zum Zitat Guan W, Pan W, Yu W et al (2021) Long-term trabecular bone score and bone mineral density changes in Chinese antiretroviral-treated HIV-infected individuals. Arch Osteoporos 16(1):41CrossRefPubMedPubMedCentral Guan W, Pan W, Yu W et al (2021) Long-term trabecular bone score and bone mineral density changes in Chinese antiretroviral-treated HIV-infected individuals. Arch Osteoporos 16(1):41CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Chen LK, Woo J, Assantachai P et al (2020) Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 21(3):300-307.e302CrossRefPubMed Chen LK, Woo J, Assantachai P et al (2020) Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 21(3):300-307.e302CrossRefPubMed
24.
Zurück zum Zitat Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1994;4(6):368–381. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1994;4(6):368–381.
25.
Zurück zum Zitat Lewiecki EM, Gordon CM, Baim S et al (2008) International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 43(6):1115–1121CrossRefPubMed Lewiecki EM, Gordon CM, Baim S et al (2008) International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 43(6):1115–1121CrossRefPubMed
26.
Zurück zum Zitat Silva BC, Leslie WD, Resch H et al (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image Journal of bone and mineral research : the official. J Am Soc Bone and Mineral Res 29(3):518–530CrossRef Silva BC, Leslie WD, Resch H et al (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image Journal of bone and mineral research : the official. J Am Soc Bone and Mineral Res 29(3):518–530CrossRef
27.
Zurück zum Zitat Venter WDF, Moorhouse M, Sokhela S et al (2019) Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med 381(9):803–815CrossRefPubMed Venter WDF, Moorhouse M, Sokhela S et al (2019) Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med 381(9):803–815CrossRefPubMed
28.
Zurück zum Zitat Venter WDF, Sokhela S, Simmons B et al (2020) Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV 7(10):e666–e676CrossRefPubMed Venter WDF, Sokhela S, Simmons B et al (2020) Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV 7(10):e666–e676CrossRefPubMed
29.
Zurück zum Zitat Erlandson KM, Kitch D, Tierney C et al (2013) Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS (London, England) 27(13):2069–2079CrossRefPubMed Erlandson KM, Kitch D, Tierney C et al (2013) Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS (London, England) 27(13):2069–2079CrossRefPubMed
30.
Zurück zum Zitat Glidden DV, Mulligan K, McMahan V et al (2018) Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin infectious dis an official publication of the Infectious Dis Socf Am 67(3):411–419CrossRef Glidden DV, Mulligan K, McMahan V et al (2018) Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin infectious dis an official publication of the Infectious Dis Socf Am 67(3):411–419CrossRef
31.
Zurück zum Zitat Hoy JF, Grund B, Roediger M et al (2017) Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START Bone Mineral Density Substudy, a randomized trial Journal of bone and mineral research : the official. J Am Soc Bone and Mineral Res 32(9):1945–1955CrossRef Hoy JF, Grund B, Roediger M et al (2017) Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START Bone Mineral Density Substudy, a randomized trial Journal of bone and mineral research : the official. J Am Soc Bone and Mineral Res 32(9):1945–1955CrossRef
32.
Zurück zum Zitat McCloskey EV, Odén A, Harvey NC et al (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX Journal of bone and mineral research : the official. J Am Soc Bone Mineral Res 31(5):940–948CrossRef McCloskey EV, Odén A, Harvey NC et al (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX Journal of bone and mineral research : the official. J Am Soc Bone Mineral Res 31(5):940–948CrossRef
33.
Zurück zum Zitat McGinty T, Cotter AG, Sabin CA et al (2019) Assessment of trabecular bone score, an index of bone microarchitecture, in HIV positive and HIV negative persons within the HIV UPBEAT cohort. PLoS ONE 14(3):e0213440CrossRefPubMedPubMedCentral McGinty T, Cotter AG, Sabin CA et al (2019) Assessment of trabecular bone score, an index of bone microarchitecture, in HIV positive and HIV negative persons within the HIV UPBEAT cohort. PLoS ONE 14(3):e0213440CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Grant PM, Kitch D, McComsey GA et al (2013) Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin infectious dis official publication Infect Dis Soc Am 57(10):1483–1488CrossRef Grant PM, Kitch D, McComsey GA et al (2013) Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin infectious dis official publication Infect Dis Soc Am 57(10):1483–1488CrossRef
35.
Zurück zum Zitat Ofotokun I, Titanji K, Vikulina T et al (2015) Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun 6:8282CrossRefPubMed Ofotokun I, Titanji K, Vikulina T et al (2015) Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun 6:8282CrossRefPubMed
36.
Zurück zum Zitat McDermott AY, Terrin N, Wanke C et al (2005) CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin infectious Dis an official publication Infec Dis Soc Am 41(11):1662–1670CrossRef McDermott AY, Terrin N, Wanke C et al (2005) CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin infectious Dis an official publication Infec Dis Soc Am 41(11):1662–1670CrossRef
Metadaten
Titel
Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males
verfasst von
Zaizhu Zhang
Qiang Lin
Ying Xu
Wenmin Guan
Xiaojing Song
Yanling Li
Yi Zhang
Taisheng Li
Wei Yu
Publikationsdatum
01.12.2023
Verlag
Springer London
Erschienen in
Archives of Osteoporosis / Ausgabe 1/2023
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-023-01238-6

Weitere Artikel der Ausgabe 1/2023

Archives of Osteoporosis 1/2023 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.